BRCA2 and Familial prostate cancer: Intriguingly, we show that BRCA2-proficient castration-resistant cancer cells become resistant to paclitaxel treatment, suggesting that BRCA2 genetic reversion or high basal levels of BRCA2 in prostate cancer patients may predict resistance to taxane-based therapy.